Tuxobertinib

DB21508InvestigationalSmall molecule

Tuxobertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Tuxobertinib is a epidermal growth factor receptor (EGFR) inhibitor. Tuxobertinib is under... Tuxobertinib is under investigation in clinical trial NCT04209465 (A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.).

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2 and Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₉H₂₉ClN₆O₄ · 561.04 g/mol (avg)
Code names: BDTX-189

Resolves to

Compound

UNII6CE2107J4TCAS2414572-47-5ChEMBLCHEMBL4650279ChEBI758185PubChem154824631

Structure

InChIKeyHIBPKFXWOPYJPZ-UHFFFAOYSA-NSMILESClC1=CC(NC2=NC=NC3=CC(OCCN4CCOCC4)=C(NC(=O)C=C)C=C23)=CC=C1OCC1=CC=CC=N1

Targets

P04626ERBB2P00533EGFR

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tuxobertinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account